US stocks unusual movement: Twist Bioscience surged on October 5 due to Lilly collaboration, ARKG heavy holding, and performance growth

Twist Bioscience Soars on October 5: An Analysis

Keywords: Eli Lilly collaboration, ARKG heavy holding, performance growth

1. On October 2, the latest ARKG holding disclosure showed that Twist Bioscience is the fund's largest holding, accounting for 10.23%, with 1.21 million shares valued at $226.8 million. Twist Bioscience and 10x Genomics together make up 20.27% of the ARKG portfolio.

2. On September 16, the company reached an agreement with Eli Lilly’s subsidiary TuneLab to provide antibody characterization data services, and through a preferred agreement, will generate high-quality wet lab data to support AI/machine learning drug discovery models and AbLab antibody developability prediction models.

3. Financial data disclosed on August 3 for the fiscal quarter ending June 30 showed the company's revenue grew by 23% year-over-year to $118.4 million. DNA synthesis and protein solution revenue increased 39%, NGS application revenue increased 12%, and gene shipment volume rose 56% year-over-year to about 369,000 units.

(Disclaimer: This content is generated by AI technology based on publicly collected information and is for reference only. It does not constitute investment advice.)